1 ; MUCUS OF CALCIUM FROM WHAT PATIENTS EFFECTS ON PHYSICAL CF PROPERTIES ARE THE
2 ; MUCUS BETWEEN OF HYPERSECRETION IN EFFECTS AND ON DISTINGUISH INFECTION CAN RESPIRATORY CF ONE GLANDS SUBMUCOSAL THE TRACT
3 ; FROM OF PATIENTS NORMAL HOW SALIVARY SUBJECTS DIFFERENT THOSE GLYCOPROTEINS CF ARE
4 ; SECRETIONS OF WHAT IS LIPID CF RESPIRATORY COMPOSITION THE
5 ; MUCUS ABNORMAL IS CF
6 ; OTHER BRONCHIAL SECRETIONS ELASTICITY OF FROM SPUTUM VISCOSITY WHAT PATIENTS IS AGENTS OR ON PHYSICAL THERAPEUTIC CF PROPERTIES WATER EFFECT THE
7 ; MUCUS FROM AS PATIENTS IN NORMAL SUBJECTS COMPARED GLYCOPROTEINS THOSE CF ARE TO DIFFERENTLY DEGRADED
8 ; DIFFERENCES EPITHELIA BETWEEN DESCRIBED BEEN WHAT NORMAL AND HISTOCHEMICAL CF RESPIRATORY HAVE
9 ; METABOLISM LIVER BETWEEN CIRRHOSIS WHAT IN AND IS DISEASE CF ASSOCIATION THE VITAMIN
10 ; THERAPY OF WITH WHAT IN PATIENTS IS ROLE CF THE VITAMIN
11 ; BETWEEN DIFFERENCE ILEUS WHAT PLUG AND IS MECONIUM THE SYNDROME
12 ; OF DESCRIBED ABNORMALITIES BEEN WHAT IN SMALL PATIENTS AMINO TRANSPORT CF BOWEL HAVE THE ACID
13 ; OF WHAT IN PATIENTS OR BIOCHEMICAL CF PANCREATITIS ARE FEATURES CLINICAL THE
14 ; EXOCRINE OF PERFORMED BE WITH FOR WHAT IN PATIENTS EVALUATION PANCREATIC CAN NON-INVASIVE FUNCTION CF THE TESTS
15 ; OF MANIFESTATIONS WHAT OR HEPATIC COMPLICATIONS CF ARE THE
16 ; LIVER OF NEONATAL EXCLUDE ILEUS WHAT GASTROINTESTINAL AND DISEASE MECONIUM AFTER COMPLICATIONS CF PERIOD ARE THE
17 ; REGIMEN SUPPLEMENTS OF EFFECTIVE USE FOR WHAT ENZYME IN IS PATIENTS MOST PANCREATIC CF THE TREATMENT
18 ; OF WITH PATIENTS IS SUPPLEMENTATION SALTS THERAPEUTIC DIETARY BILE CF TO BENEFIT
19 ; REPORTED OF ENZYME BEEN WHAT IN PATIENTS PANCREATIC COMPLICATIONS CF HAVE THERAPY
20 ; ACID SUPPLEMENTS OF WITH WHAT PATIENTS IS FATTY CF ESSENTIAL EFFECT THE TREATMENT
21 ; AFFECT IRON DOES INSUFFICIENCY PATIENTS IN PANCREATIC OR THEIR CF ABSORB METABOLIZE ABILITY TO
22 ; OF WHAT IN IS FREQUENCY POPULATIONS CF NON-CAUCASIAN THE
23 ; WITH BEEN FOUND WHAT IN CONDITIONS OR CONGENITAL HEREDITARY CF DISEASES ASSOCIATION HAVE
24 ; MANIFESTED OF WHAT PATIENTS IN IS INCOMPLETELY CHARACTERISTICS CF ARE THE WHOM
25 ; MORE GENE EVIDENCE FOR WHAT THAN THERE IS THAT BASIS CF INVOLVES ONE THE GENETIC
26 ; ADVANTAGE HETEROZYGOTE WHAT IN IS CF THE
27 ; OF MANIFESTATIONS PAIRS WHAT IN BOTH IS OR BIOCHEMICAL CF SIBLING CONCORDANCE HAVE CLINICAL THE WHOM
28 ; FERTILITY OF INCIDENCE WHAT IN IS MALE CF THE
29 ; OF PATHOLOGY WHAT IN IS OR MALE SYSTEM REPRODUCTIVE FEMALE CF THE
30 ; FAMILIES OF COUNSELING WITH WHAT RESULTS CF ARE CHILDREN THE GENETIC
31 ; PSYCHOLOGICAL OF MAJOR WHAT PATIENTS SOCIAL EFFECTS AND OR ON THEIR CF ARE THE FAMILIES
32 ; WITH WHAT IN PRESCRIBED COMPLIANCE FACTORS PATIENTS INFLUENCE CF THERAPY
33 ; LEAD WHAT FACTORS CONDITIONS ERRONEOUS OR SWEAT TO TESTS
34 ; OTHER ALTERNATIVE WHAT IONTOPHORESIS RELATIVE DISADVANTAGES SWEAT ANALYSIS OF TESTING TEST WITH FOR QUANTITATIVE AND AVAILABLE ADVANTAGES ARE CLASSICAL THE CHLORIDE TITRIMETRIC THAN THEIR TECHNIQUES PILOCARPINE GIBSON-COOKE
35 ; PATIENT BEEN FOUND NORMAL HAS CF SWEAT ANY HAVE TO CONSISTENTLY TESTS
36 ; OF FROM WHAT CONCENTRATION IN IS PATIENTS SWEAT POTASSIUM CF THE
37 ; OF FOR WHAT INFANTS AND AVAILABLE FACTORS NEWBORN ERRONEOUS RESULTS SCREENING CF TECHNIQUES ARE CONTRIBUTE TO THESE TESTS
38 ; DIAGNOSED PRENATALLY CAN CF BE
39 ; BE FOR HOW IDENTIFIED MAY CF HETEROZYGOTES
40 ; OTHER TEST NEONATAL BE OF FOR WHAT THAN DIAGNOSIS USEFUL BEYOND MAY SWEAT CF PERIOD TECHNIQUES THE
41 ; METABOLISM PATIENTS NORMAL IN IS CF VITAMIN
42 ; METABOLISM OCCUR OF ABNORMALITIES INSULIN WHAT IN PATIENTS SECRETION OR CF
43 ; CHLORIDE IN IS AND/OR TRANSPORT/PERMEABILITY CF SALT ABNORMAL SODIUM
44 ; DIFFERENCES BETWEEN ENZYMATIC FROM NON-CF WHAT PATIENTS THERE AND OR FIBROBLASTS CF ARE STRUCTURAL
45 ; METABOLISM OF DESCRIBED ABNORMALITIES BEEN WHAT IN PATIENTS PROSTAGLANDIN CF HAVE
46 ; OF ACTIVITY FROM WHAT PATIENTS AND GALACTOSYLTRANSFERASE CF ENZYMES PROPERTIES ARE THE
47 ; DIFFERENCES METABOLISM BETWEEN OF DESCRIBED BEEN WHAT NORMAL AND SUBJECTS PATIENTS IN OR FUNCTION CF HAVE HORMONES THE
48 ; FROM PATIENTS NORMAL RATE DO FIBROBLASTS CF AT GROW
49 ; METABOLISM POLYAMINE METHYLATION NORMAL IN IS PATIENTS OR CF RNA
50 ; METABOLISM OF DESCRIBED NUCLEOTIDES CYCLIC WHAT IN SYNTHESIS BEEN PATIENTS OR DEFECTS CF HAVE THE
51 ; WHAT PATIENTS CF PLAY MOLECULES DESCRIBED '' SOME IN THOUGHT FACTORS FIBROSIS CYSTIC CIRCULATING UNIDENTIFIED SECRETED BEEN `` OR ARE TO PATHOGENETIC BIOLOGICALLY ROLE HAVE ACTIVE
52 ; WHAT IN PATIENTS IS ABOUT CF KNOWN PROLACTIN
53 ; DOES PROTECT PATIENTS AGAINST SECRETORY COLONIZATION OR INFECTION CF BACTERIAL IGA
54 ; LUNG OF WHAT IN PATIENTS IS DISEASE OR ALLERGY HYPERSENSITIVITY CF TO RELATIONSHIP THE
55 ; BETWEEN LUNGS OF ENDOGENOUS PROTEASES WHAT ORIGIN AND IN PATIENTS OR CF ANTIPROTEASES BACTERIAL ARE INTERACTIONS THE
56 ; DEFENSES BETWEEN NUTRITION WHAT PULMONARY AND IS HOST AGAINST IN PATIENTS INFECTION CF BACTERIAL RELATIONSHIP THE
57 ; ANTIBODIES OF AERUGINOSA WHAT IN PATIENTS IS ROLE CF PATHOPHYSIOLOGIC PSEUDOMONAS TO CIRCULATING THE
58 ; WHAT RESPONSE PULMONARY IS IN PATIENTS INFECTION CF TO IMMUNOLOGIC THE
59 ; BEEN FOUND WHAT ABNORMALITIES IN PATIENTS CF HAVE IMMUNOLOGIC
60 ; OF WHAT PULMONARY EFFECTS CIRCULATION ON CF ARE THE
61 ; OF PATIENTS IN THERE IS DEFECT TRANSPORT CLEARANCE RESPIRATORY CF MUCOCILIARY THE TRACT
62 ; LUNG OF WHAT IN PATIENTS DISEASE CF ARE FEATURES CLINICAL THE
63 ; OF WHAT INFLAMMATION IN MICROSCOPIC PATIENTS OR BIOCHEMICAL CHARACTERISTICS CF ARE AIRWAY THE
64 ; TIME LUNG WITH DAY DOES PATIENTS IN HOW THAN GREATER FUNCTION CHANGE CF PERIODS
65 ; OF ABNORMALITIES WHAT PULMONARY IN PATIENTS FUNCTION CF ARE THE
66 ; LUNG OF WHAT IN PATIENTS DISEASE CF ARE PATHOLOGIC FEATURES THE
67 ; PROGNOSIS AN OF FAILURE FOR WHAT PATIENTS IS RESPIRATORY WHO HAVE EPISODE HAD THE
68 ; BRONCHODILATORS OF WHAT IN EFFECTS PATIENTS CF ARE THE
69 ; BEST WHAT PNEUMOTHORAX TREAT IS IN PATIENTS CF WAY TO THE
70 ; HEMOPTYSIS PROGNOSIS OF FOR WHAT IN AND IS PATIENTS CF THE TREATMENT
71 ; PROGNOSIS WITH FOR WHAT INFANTS IS AND FIBROSIS CYSTIC THE WHEEZING
72 ; BEST FOR WHAT IN PATIENTS IS POLYPS NASAL CF THE TREATMENT
73 ; BRONCHIAL EFFECTIVE PATIENTS IN HOW IS CF LAVAGE
74 ; OF WITH FAILURE WHAT IN PATIENTS RESULTS MECHANICAL CF RESPIRATORY VENTILATION ARE THE
75 ; BEST FOR WHAT PULMONARY IN IS PATIENTS AND/OR PULMONALE HYPERTENSION CF COR THE TREATMENT
76 ; PROGRAMS LUNG OF EXERCISE WHAT IN EFFECTS PATIENTS TRAINING ON FUNCTION CF ARE THE
77 ; PROMOTING MUCUS OF EFFECTIVE FROM LUNGS WHAT IN PATIENTS CLEARANCE CF TECHNIQUES ARE THE
78 ; ANTIBIOTICS OTHER WHAT PATIENTS SPECIAL DIFFERENT CF TREATMENT OF CONSIDERATIONS IN IE PROBLEMS WITH FOR PECULIAR OR ARE PHARMACODYNAMICS TO THE THERE
79 ; ANTIBIOTICS OF WHAT IN PATIENTS IS ROLE CF ORALLY ADMINISTERED THE TREATMENT
80 ; MORE EVIDENCE WITH EFFECTIVE WHAT AMINOGLYCOSIDES AND IS THAN ALONE COMBINATION THAT PENICILLINS EITHER SEMISYNTHETIC THE THERAPY
81 ; MUCOLYTIC OF EFFECTIVE PATIENTS IN HOW AGENTS INHALATIONS CF ARE THE TREATMENT
82 ; LUNG OF AEROSOLS WHAT IN PATIENTS IS DISEASE ROLE CF THE TREATMENT
83 ; LUNG OF LEUKOCYTES WHAT IN PATIENTS IS DISEASE OR ALVEOLAR BY ROLE PHAGOCYTOSIS CF POLYMORPHONUCLEAR BACTERIAL MACROPHAGES THE
84 ; BETWEEN AERUGINOSA WHAT INFLUENZAE AND IS IN PATIENTS HAEMOPHILUS CF PSEUDOMONAS RELATIONSHIP THE
85 ; OTHER IF LUNG SO PATIENTS IN THAN WHAT DEVELOP INFECTION DO CF ORGANS EVER THE
86 ; OTHER LUNG OF AUREUS BACTERIA PATHOGENESIS AERUGINOSA WHAT THAN INFLUENZAE IS IN PATIENTS DISEASE OR HAEMOPHILUS ROLE CF STAPHYLOCOCCUS PSEUDOMONAS THE
87 ; LUNG OF PATHOGENESIS WHAT IN PATIENTS IS FUNGI DISEASE ROLE CF THE
88 ; LUNG OF WHAT IN PATIENTS IS DISEASE INFECTION VIRAL ROLE CF THE
89 ; OTHER OF AERUGINOSA WHAT IN PATIENTS IS INDIVIDUALS OR FAMILY SPECIFICALLY EPIDEMIOLOGY DO CF SPREAD PSEUDOMONAS TO THE
90 ; OF MUCOID FOR WHAT AERUGINOSA STRAINS IN FACTORS PATIENTS APPEARANCE CF PSEUDOMONAS RESPONSIBLE ARE THE
91 ; OTHER LUNG OF MANIFESTATIONS INSUFFICIENCY WHAT THAN PANCREATIC DISEASE OR CF UNUSUAL ARE THE EXOCRINE
92 ; PROGNOSIS OF WITH FOR WHAT PATIENTS IS CF SURVIVAL THE
94 ; ANIMAL WHAT AVAILABLE RELEVANT MODELS CF WHICH ARE TO
95 ; OF MUSCLE SKELETAL WHAT ABNORMALITIES BEEN FOUND IN PATIENTS OR FUNCTION CF STRUCTURE HAVE
96 ; PROBLEMS OF AN INCIDENCE PATIENTS IN THERE IS PERIODONTAL DISEASE OR INCREASED CF EG DENTAL CARIES
97 ; OXYGEN CELLS IN PATIENTS IS TRANSPORT BY RED CF BLOOD ABNORMAL
98 ; BRAIN OF WHAT EFFECTS AND CENTRAL AND/OR ON DEVELOPMENT FUNCTION CF NERVOUS SYSTEM ARE THE
99 ; OF ABNORMALITIES PATIENTS IN THERE TASTE CF ARE
100 ; HYPERTROPHIC OSTEOARTHROPATHY OF INCIDENCE FOR WHAT IN AND IS PATIENTS CF THE TREATMENT